REVISTA CHILENA DE ENFERMEDADES RESPIRATORIAS

228

Cigarette smoke-induced pulmonary inflammation and

emphysema are attenuated in CCR6-deficient mice. J

Immunol. 2006; 177: 4350-9.

4.- Global Initiative for Chronic Obstructive Lung Disease

(GOLD). Global strategy for Diagnosis, Management

and Prevention of Chronic Obstructive Pulmonary Dis-

ease. 2011. Arch Bronconeumol. 2013; 49: 354-63.

5.- Vestbo J, Hurd SS, Agustí AG, Jones PW,

Vogelmeier C, Anzueto A, et al.

Global strat- egy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD exec- utive summary.

Am J Respir Crit Care Med. 2013; 187:

347-65.

6.- MENEZES AM, PÉREZ-PADILLA R, JARDIM JR,

MUI˜NO A, LóPEZ MV, VALDIVIA G, et al. Chronic

obstructive pulmonary disease in five Latin American

cities (the PLATINO study): A prevalence study. Lancet

2005; 366: 1875-81.

7.-

Wedzicha JA,

Banerji D,

Chapman KR, Vestbo J, Roche N, Ayers RT

, et al. Indacater-

ol-Glycopyrronium

versus

Salmeterol-Fluticasone for

COPD. N Engl J Med 2016; 374: 2222-34.

8.-

Calverley PM,

Anderson JA,

Celli B, Ferguson GT

Jenkins C,

Jones PW

, et al.

Salmeterol and fluticasone propionate and survival in

chronic obstructive pulmonary disease.

N Engl J Med

2007; 356: 775-89.

Tashkin DP

Celli B,

Senn S,

Burkhart D, Kesten S, Menjoge S,

et al. A 4-year trial of

tiotropium in chronic obstructive pulmonary disease.

N Engl J Med.

2008 Oct 9; 359: 1543-54.

10.

Larsson K,

Janson C,

Lisspers K,

Jør- gensen L,

Stratelis G,

Telg G,

et al. Com-

bination of budesonide/formoterol more effective than

fluticasone/salmeterol in preventing exacerbations

in chronic obstructive pulmonary disease: the PATHOS

study.

J Intern Med.

2013; 273: 584-94.

11.-

Shahab L,

Jarvis MJ,

Britton J, West R.

Prevalence, diagnosis and relation to tobacco depen-

dence of chronic obstructive pulmonary disease in a

nationally representative population sample. Thorax

2006; 61: 1043.7.

12.- Anthonisen NR, Connett JE, Kiley JP,

Altose MD, Bailey W, Buist S, et al. Effects of

smoking intervention and the use of an inhaled anticho-

linergic bronchodilator on the rate of decline of FEV1:

The Lung Health Study. JAMA 1994; 272: 1497-505.

13.-

Jiménez Ruiz C, Ramos Pinedo A, Cicero Guerrero A, Mayayo Ulibarri M,

Cris- tobal Fernández M, López González G.

Characteristics of COPD smokers and effectiveness and

safety of smoking cessation medications.

Nicotine Tob Res.

2012; 14: 1035-9.

14. Masefield S, Powell P, Jiménez-Ruiz C,

Hajek P, Lewis K, Andreas S, et al. Recommen-

dations to improve smoking cessation outcomes from

people with lung conditions who smoke. ERJ Open Res

2016; 2: 00009-2016.

15.-

Jiménez-Ruiz CA,

Riesco Miranda JA, Altet Gómez N, Lorza Blasco JJ, Signes- Costa Miñana J,

Solano Reina S,

et al.

Sociedad Española de Neumología y Cirugía Torácica (SEPAR).

Treatment of smoking in smokers with

chronic obstructive pulmonary disease. Sociedad Espa-

ñola de Neumología y Cirugía Torácica (SEPAR).

Arch Bronconeumol.

2013; 49: 354-63.

16.- Kanner RE, Connett JE, Williams DE,

Buist AS. Effects of randomized assignment to a

smoking cessation intervention and changes in smoking

habits on respiratory symptoms in smokers with early

chronic obstructive pulmonary disease: the Lung Health

Study. Am J Med 1999; 106: 410-6.

17.- Tønnesen P, Mikkelsen K, Bremann L.

Nurse-conducted smoking cessation in patients with

COPD using nicotine sublingual tablets and behavioral

support. Chest 2006; 130: 334-42.

18.- Barnett M. COPD: Smoking cessation Community

Nursing Journal 2008; 22: 36-40.

19.- Laniado-Laborín R. Smoking and Chronic

Obstructive Pulmonary Disease (COPD). Parallel Ep-

idemics of the 21st Century. Int J Environ Res Public

Health 2009; 6: 209-24.

20.-

Jiménez-Ruiz CA,

Andreas S,

Lewis KE, Tonnesen P

van Schayck CP

Hajek P,

al. Statement on smoking cessation in COPD and other

pulmonary diseases and in smokers with comorbidities

who find it difficult to quit.

Eur Respir J

2015; 46: 61-

79.

21.- Hoogendoorn M, Feenstra TL, Hoogen-

veen RT, Rutten-van Mölken MPMH. Long

term effectiveness and cost-effectiveness of smoking

cessation interventions in patients with COPD. Thorax

2010; 65: 711-8.

22.- Tashkin DP, Rennard S, Hays JT, Law-

rence D, Marton JP, Lee TC. Effects of va-

renicline on smoking cessation in patients with mild to

moderate COPD: A randomized controlled trial. Chest

2011; 139: 591-9.

23.- Tashkin DP, Kanner R, Bailey W, Buist S,

Anderson P, Nides M, et al. Smoking cessation

in patients with chronic obstructive pulmonary disease:

A doubleblind, placebo-controlled, randomised trial.

Lancet 2001; 357: 1571-5.

24.- Wagena EJ, Knispchild PG, Huibers MJ,

Wouters EF, van Schayk CP. Efficacy of bu-

propión and nortriptyline for smoking cessation among

people at risk for or with COPD. Arch Intern Med 2005;

165: 2286-92.

25.- Strassmann R, Bausch B, Spaar A, Klei-

jnen J, Braendli O, Puhan MA. Smoking ces-

sation interventions in COPD: A network meta-analysis

of randomised trials. Eur Respir J 2009; 34: 634-40.

F. Arancibia H.

Rev Chil Enferm Respir 2017; 33: 225-229